Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIV(mac251) Acquisition

The recombinant ALVAC vaccine coupled with the monomeric gp120/alum protein have decreased the risk of HIV and SIV acquisition. Ab responses to the V1/V2 regions have correlated with a decreased risk of virus acquisition in both humans and macaques. We hypothesized that the breadth and functional pr...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Immunol
Main Authors: Gordon, Shari N., Liyanage, Namal P. M., Doster, Melvin N., Vaccari, Monica, Vargas-Inchaustegui, Diego A., Pegu, Poonam, Schifanella, Luca, Shen, Xiaoying, Tomaras, Georgia D., Rao, Mangala, Billings, Erik A., Schwartz, Jennifer, Prado, Ilia, Bobb, Kathryn, Zhang, Wenlei, Montefiori, David C., Foulds, Kathryn E., Ferrari, Guido, Robert-Guroff, Marjorie, Roederer, Mario, Phan, Tran B., Forthal, Donald N., Stablein, Donald M., Phogat, Sanjay, Venzon, David J., Fouts, Timothy, Franchini, Genoveffa
פורמט: Artigo
שפה:Inglês
יצא לאור: AAI 2016
נושאים:
Immunotherapy and Vaccines
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5026031/
https://ncbi.nlm.nih.gov/pubmed/27591322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1600674
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים